Discover Cipher Mining's Q3 2025 strategic pivot to high-performance computing with major AWS, Google deals, rising revenues, and robust future growth.
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
RBC Capital Markets downgraded Bicycle Therapeutics ( BCYC) to sector perform from outperform, saying "pipeline programs are taking more time to reach inflection points." The bank cut its price target ...
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.
Eyecare company Bausch + Lomb (NYSE:BLCO) in Q3 CY2025, with sales up 7.1% year on year to $1.28 billion. The company’s ...